Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer

ConclusionsFor the treatment of advanced/metastatic MTC, no specific preference of sequencing systemic agents was observed in the first- and second-line settings. Considering the recent approval of selectiveRET inhibitors for patients withRET-mutant MTC, future research should investigate how treatment patterns evolve for these patients.
Source: Thyroid Research - Category: Endocrinology Source Type: research